ProCE Banner Activity

Immunotherapy in Advanced/Metastatic HCC


Slides from a 2024 live ASCO satellite symposium, covering the recent developments in the rapidly evolving landscape of advanced/metastatic HCC, including the use of Barcelona Clinic Liver Cancer staging for disease characterization and selecting primary therapy, clinical trial updates for immunotherapy plus VEGF inhibitors, and expert considerations on the latest practice changing results presented at the ASCO annual meeting.

Released: May 29, 2024

Expiration: May 28, 2025



Richard S. Finn

Richard S. Finn, MD

Department of Medicine
Division of Hematology/Oncology
UCLA David Geffen School of Medicine
Medical Director, Clinical Research Unit
Director, Signal Transduction and Therapeutics Program
University of California, Los Angeles
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an educational grant from AstraZeneca.